

CURRENT REPORT 24/2024

June 17, 2024

Fulfillment of conditions for the disbursement of the Tranche B of financing from the European Investment Bank

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow („**Company**”), with reference to current reports no. 14/2022 of August 17, 2022, no. 19/2023 of May 5, 2023, no. 33/2023 of June 19, 2023, no. 2/2024 of January 17, 2024, no. 4/2023 of January 30, 2024, and no. 12/2024 of March 6, 2024 (subsequently amended by a current report 12K/2024 dated March 7, 2024) hereby informs that on June 17, 2024, the Company received from the European Investment Bank (“**EBI**”) confirmation that the Company has fulfilled all conditions for the disbursement of the second tranche of financing (“**Tranche B**”) under the financing agreement concluded on August 16, 2022.

As a result, the Company expects to receive on June 25, 2024, an amount of EUR 8,000,000.00 (34,864,800.00 PLN converted at the average exchange rate of the National Bank of Poland on June 14, 2024, 1 EUR = 4.3581). The Company is obligated to repay Tranche B by June 25, 2029.

The Management Board informs that as of June 14, 2024, the value of the Company's cash and bonds amounted to PLN 224,575,611.00. This value does **not include** the expected receipt of Tranche B on June 25, 2024, in the amount of EUR 8,000,000.00 as described above.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Article 17.1 of MAR

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board